Pluristem CEO Issues Shareholder Update
15 sept. 2020 07h30 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
27 août 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
19 août 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
17 août 2020 02h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
10 août 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem CEO Issues Shareholder Update on Clinical Programs
21 juil. 2020 07h10 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
11 juin 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
03 juin 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
Collaboration will enable Pluristem to develop new technologies relying on its PLX platformThe consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program, and...
Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
14 mai 2020 08h00 HE
|
Pluristem Therapeutics, Inc.
87.5% survival rate of patients on invasive mechanical ventilation injected with PLX cells75% of patients no longer in need of any mechanical ventilation 62.5% of the patients discharged alive from...
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
08 mai 2020 06h00 HE
|
Pluristem Therapeutics, Inc.
140 patients with severe COVID-19 and ARDS to be treatedPrimary endpoint: ventilator free days during the main 28-day study period, secondary endpoint includes survival rate and ICU free days HAIFA,...